Cendakimab

DB18427InvestigationalProtein Based Therapies

Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.

Mechanism
Curator reviewed
Also known as
HUMANIZED ANTI-HUMAN IL-13 MONOCLONAL ANTIBODY · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL-13 (INTERLEUKIN 13, IL-13)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-453) (VH (HOMO SAPIENS IGHV2-5*08 (80.6%) -(IGHD) -IGHJ4*01 (100%)) (10.7.15) (1-123) -HOMO SAPIENS IGHG1*03V, G1M3>G · IMMUNOGLOBULIN G1(240-ALANINE, 241-ALANINE), ANTI-(HUMAN INTERLEUKIN 13) (HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .GAMMA.-1), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .KAPPA.-1, DIMER
Code names
ABT-308 · BMS-986355 · CC-93538

Resolves to

Compound
UNIIO8R9U9ZUVN
Targets
P35225IL13

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cendakimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In